Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Elevance Health Inc (NYSE: ELV) was $362.34 for the day, up 1.36% from the previous closing price of $357.49. In other words, the price has increased by $1.36 from its previous closing price. On the day, 1.82 million shares were traded. ELV stock price reached its highest trading level at $364.78 during the session, while it also had its lowest trading level at $357.935.
Ratios:
Our analysis of ELV’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.64.
On July 18, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $310.
Robert W. Baird Downgraded its Outperform to Neutral on April 15, 2025, while the target price for the stock was maintained at $529.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 19 ’25 when DeVore Susan D. bought 1,200 shares for $312.15 per share. The transaction valued at 374,580 led to the insider holds 3,502 shares of the business.
BOUDREAUX GAIL bought 8,500 shares of ELV for $2,438,951 on Jul 18 ’25. The President and CEO now owns 151,020 shares after completing the transaction at $286.94 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the EVP & CFO of the company, sold 4,588 shares for $424.82 each. As a result, the insider received 1,949,074 and left with 18,977 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 81591107584 and an Enterprise Value of 77114105856. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.42, and their Forward P/E ratio for the next fiscal year is 11.85. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 9.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.43 while its Price-to-Book (P/B) ratio in mrq is 1.86. Its current Enterprise Value per Revenue stands at 0.407 whereas that against EBITDA is 8.128.
Stock Price History:
The Beta on a monthly basis for ELV is 0.59, which has changed by -0.26380593 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $510.24, while it has fallen to a 52-week low of $273.71. The 50-Day Moving Average of the stock is 16.31%, while the 200-Day Moving Average is calculated to be -2.05%.
Shares Statistics:
ELV traded an average of 2.44M shares per day over the past three months and 1867130 shares per day over the past ten days. A total of 224.84M shares are outstanding, with a floating share count of 224.70M. Insiders hold about 0.21% of the company’s shares, while institutions hold 92.81% stake in the company. Shares short for ELV as of 1757894400 were 3677507 with a Short Ratio of 1.51, compared to 1755216000 on 3156964. Therefore, it implies a Short% of Shares Outstanding of 3677507 and a Short% of Float of 1.63.
Dividends & Splits
With its trailing 12-month dividend rate of 6.68, ELV has a forward annual dividend rate of 6.76. Against a Trailing Annual Dividend Yield of 0.018685838. The stock’s 5-year Average Dividend Yield is 1.24. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-09-10 with an ex-dividend date of 2025-09-10. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
A comprehensive evaluation of Elevance Health Inc (ELV) is underway, with the input of 17.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $4.1, with high estimates of $4.54 and low estimates of $1.96.
Analysts are recommending an EPS of between $30.32 and $28.77 for the fiscal current year, implying an average EPS of $29.89. EPS for the following year is $31.45, with 21.0 analysts recommending between $38.47 and $26.97.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 10 analysts. It ranges from a high estimate of $50.2B to a low estimate of $48.65B. As of. The current estimate, Elevance Health Inc’s year-ago sales were $44.72BFor the next quarter, 10 analysts are estimating revenue of $49.46B. There is a high estimate of $50.9B for the next quarter, whereas the lowest estimate is $48.17B.
A total of 11 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $199.04B, while the lowest revenue estimate was $195.21B, resulting in an average revenue estimate of $197.03B. In the same quarter a year ago, actual revenue was $175.2BBased on 10 analysts’ estimates, the company’s revenue will be $206.74B in the next fiscal year. The high estimate is $213.85B and the low estimate is $199.92B.
